Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Antitumor agent-101 is a selective, covalent inhibitor targeting lysine methyltransferases G9a/GLP, demonstrating IC50 values of 8.5 nM for G9a and 5.5 nM for GLP. It exhibits antitumor efficacy in the PANC-1 xenograft model [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,520.00 | |
50 mg | 8-10 weeks | $ 1,980.00 | |
100 mg | 8-10 weeks | $ 2,500.00 |
Description | Antitumor agent-101 is a selective, covalent inhibitor targeting lysine methyltransferases G9a/GLP, demonstrating IC50 values of 8.5 nM for G9a and 5.5 nM for GLP. It exhibits antitumor efficacy in the PANC-1 xenograft model [1]. |
Targets&IC50 | G9a:8.5 nM, GLP:5.5 nM |
In vitro | Antitumor agent-101 (Compound 27) (0-5 μM; 48 hours) inhibits proliferation and colony formation in PANC-1 and MDA-MB-231 cells [1]. Additionally, Antitumor agent-101 (0-10 μM; 0-96 hours) effectively reduces H3K9me2 levels in PANC-1 and MDA-MB-231 cells in a concentration- and time-dependent manner. |
In vivo | Antitumor agent-101 (Compound 27), administered at 2 mg/kg via intraperitoneal injection five times per week, inhibits the growth of PANC-1 xenograft tumors by suppressing the methyltransferase activity of G9a/GLP [1]. Additionally, this compound demonstrates a peak plasma concentration (Cmax) of 316 ng/mL and a mean residence time (MRT) of 0.61 hours [1]. |
Molecular Weight | 482.62 |
Formula | C26H38N6O3 |
CAS No. | 2848632-52-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Antitumor agent-101 2848632-52-8 Chromatin/Epigenetic Histone Methyltransferase inhibitor inhibit